UNA oligomers with reduced off-target effects in gene silencing
阅读说明：本技术 在基因沉默中具有降低的脱靶效应的una寡聚物 (UNA oligomers with reduced off-target effects in gene silencing ) 是由 立川洁 约瑟夫·E·佩恩 帕德马纳巴·契吾库拉 于 2015-03-24 设计创作，主要内容包括：本发明提供用于以降低的脱靶效应进行基因沉默的UNA寡聚物。所述UNA寡聚物可以含有第一链和第二链,每条链长度为19-29个单体,所述单体为UNA单体和不同的核酸单体。实施方案包括药物组合物和用于通过向对象施用UNA寡聚物来以降低的脱靶效应治疗或预防TTR相关淀粉样变性的方法。(The present invention provides UNA oligomers for gene silencing with reduced off-target effects. The UNA oligomer can comprise a first strand and a second strand, each strand being 19-29 monomers in length, the monomers being UNA monomers and different nucleic acid monomers. Embodiments include pharmaceutical compositions and methods for treating or preventing TTR-associated amyloidosis with reduced off-target effects by administering a UNA oligomer to a subject.)
1. A UNA oligomer for inhibiting expression of a target gene, the oligomer comprising a first strand and a second strand, each strand being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, wherein the oligomer has a duplex structure of 14 to 29 monomers in length, and wherein the oligomer has reduced off-target effects compared to an siRNA with the same target, and wherein the oligomer comprises a sequence selected from the group consisting of:
wherein
2. The UNA oligomer of claim 1, wherein the second strand is a guide strand for RNA interference and the first strand is a passenger strand for RNA interference.
3. The UNA oligomer of claim 1, wherein the first strand and second strand are joined and form a duplex region with a loop at one end.
4. The UNA oligomer of claim 1, wherein the UNA oligomer inhibits TTR expression with reduced off-target effects.
5. The UNA oligomer of claim 1, wherein the oligomer inhibits TTR expression in vivo.
6. A pharmaceutical composition comprising the UNA oligomer of any one of claims 1-5 and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6, wherein the composition is capable of local or systemic administration.
8. The pharmaceutical composition of claim 6, wherein the composition is capable of intravenous, subcutaneous, pulmonary, intramuscular, intraperitoneal, dermal, or oral administration.
9. The pharmaceutical composition of claim 6, comprising a lipid formulation.
10. The pharmaceutical composition of claim 6, comprising one or more lipids selected from the group consisting of: cationic lipids, anionic lipids, sterols, and pegylated lipids.
11. The pharmaceutical composition of claim 6, wherein the composition is substantially free of liposomes.
12. The pharmaceutical composition of claim 6, wherein the composition comprises a liposome.
13. Use of the UNA oligomer of any one of claims 1-5 or the pharmaceutical composition of any one of claims 6-12 in the manufacture of a medicament for treating or preventing TTR-associated amyloidosis in a subject.
14. The use of claim 13, wherein the TTR-associated amyloidosis is ATTR.
15. The use of claim 13, wherein the medicament reduces TTR in the subject by at least 10% with reduced off-target effects compared to a control.
16. The use according to claim 13, wherein the medicament comprises a dose of 0.001-50.0 mg/kg.
17. The use of claim 13, wherein expression of TTR mRNA is reduced for at least 5 days.
Technical Field
The present invention relates to the field of biomedicine and therapy which can be operated by gene silencing. More specifically, the invention relates to structures, compositions and uses of agents with reduced off-target effects in gene silencing. The active agent is a UNA oligomer useful for gene silencing, as well as in methods for treating transthyretin-associated amyloidosis, and the like.
Background
A major drawback of gene silencing techniques such as RNA interference is the occurrence of off-target effects. Off-target effects occur when a gene silencing agent has an effect on a gene product that is not its target and is therefore harmful. Off-target effects are becoming one of the major obstacles to the development of gene silencing therapeutics.
One approach to reducing off-target effects is to judiciously design the structure of the gene silencing agent to avoid effects on genes other than the desired target. In some cases, the gene silencing agents may be mixed such that the concentration of the agent with a particular off-target effect is reduced. In other cases, the gene silencing agent may be chemically modified to avoid off-target effects. These conventional methods have been able to reduce off-target effects, but they are difficult to implement.
What is needed are gene silencing agents with reduced off-target effects.
There is a long-felt need for methods and compositions for therapeutic oligomers by RNA interference manipulation that avoid or reduce off-target effects.
Summary of The Invention
The invention provides agents for gene silencing and methods of using the agents to treat or prevent disease.
In particular, the active agent is a UNA oligomer with reduced off-target effects in gene silencing.
The UNA oligomer of the present invention is an unlocked nucleomonomer active agent (UNA) described in detail below.
UNA oligomers of the invention are useful for gene silencing against a wide range of gene targets with reduced off-target effects.
In certain aspects, the invention provides UNA oligomers for inhibiting ApoCIII expression.
In some aspects, the invention provides a method for treating amyloidosis. More specifically, the invention relates to methods of treating transthyretin-associated amyloidosis with UNA oligomers having reduced off-target effects in the knock-down of transthyretin.
In certain aspects, the invention provides UNA oligomers for inhibiting TTR expression and V30M TTR expression that are useful for treating amyloidosis with reduced off-target effects. The UNA oligomer can comprise a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers being UNA monomers and nucleic acid monomers. Embodiments include pharmaceutical compositions and methods of treating or preventing TTR-associated amyloidosis with reduced off-target effects by administering a UNA oligomer to a subject.
In certain aspects, UNA oligomers of the invention can be used for gene silencing in plants.
Embodiments of the invention include the following:
a UNA oligomer for inhibiting expression of a target gene, the oligomer comprising a first strand and a second strand, each strand being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, wherein the oligomer has a duplex structure of 14 to 29 monomers in length, and wherein the oligomer has a reduced off-target effect compared to an siRNA with the same target.
The above UNA oligomer, wherein the second strand is a guide strand for RNA interference (guide strand), and the first strand is a passenger strand for RNA interference (passager strand). The above UNA oligomer, wherein the UNA oligomer comprises a UNA monomer at the first position at the 1 end of the first strand, a UNA monomer at one or both of the last two positions at the 3 end of the first strand, and a UNA monomer at one or both of the last two positions at the 3 end of the second strand.
The above UNA oligomer, wherein the UNA oligomer comprises a UNA monomer at the first position at the 1-terminus of the first strand, and a UNA monomer at one or both of the last two positions at the 3-terminus of the first strand. The above UNA oligomer, wherein the UNA oligomer comprises a UNA monomer at the first position at the 1-terminus of the first strand and a UNA monomer at one or both of the last two positions at the 3-terminus of the second strand.
The UNA oligomer above, wherein the UNA oligomer comprises a UNA monomer at the first position at the 1-terminus of the first strand. The above UNA oligomer, wherein the UNA oligomer comprises a UNA monomer at one or both of the last two positions at the 3-terminus of the first strand, and a UNA monomer at one or both of the last two positions at the 3-terminus of the second strand.
The UNA oligomer above, wherein the UNA oligomer has one or two overhangs (overhand). The UNA oligomer above, wherein the UNA oligomer inhibits the expression of TTR with reduced off-target effects. The above UNA oligomer, wherein the UNA oligomer inhibits expression of an apolipoprotein gene with reduced off-target effects.
The UNA oligomer of above, wherein the oligomer inhibits expression of TTR in vivo.
The above UNA oligomer, wherein the UNA oligomer is targeted to inhibit gene expression in a plant with reduced off-target effects.
The above UNA oligomer, comprising at least one nucleic acid monomer that is base-modified, sugar-modified, or linkage-modified.
The UNA oligomer above, wherein the oligomer comprises an amino acid sequence selected from SEQ ID NOs: 3-32.
The above UNA oligomer, wherein the oligomer comprises a UNA monomer at any one or more of positions 2-8 at the 5' end of the second strand.
A pharmaceutical composition comprising the above UNA oligomer and a pharmaceutically acceptable carrier.
The above pharmaceutical composition, wherein said composition is capable of local or systemic administration.
The above pharmaceutical composition, wherein said composition can be administered intravenously, subcutaneously, pulmonarily, intramuscularly, intraperitoneally, dermally or orally.
The above pharmaceutical composition, comprising a lipid formulation.
The above pharmaceutical composition comprising one or more lipids selected from the group consisting of: cationic lipids, anionic lipids, sterols, pegylated lipids, and any combination of the foregoing.
The pharmaceutical composition above, wherein the composition is substantially free of liposomes.
The above pharmaceutical composition, wherein the composition comprises a liposome.
A method of treating or preventing TTR-associated amyloidosis, comprising administering to a subject in need thereof an effective amount of the above UNA oligomer.
The method above, wherein the TTR-associated amyloidosis is ATTR. The method above, wherein the subject is a human. The above method compared to a control, wherein the method reduces TTR in the subject by at least 10% with reduced off-target effects.
The above method, wherein the effective amount is a dose of 0.001 to 50.0 mg/kg. The above method, wherein expression of TTR mRNA is reduced for at least 5 days.
The above method, wherein the method reduces peripheral neuropathy or autonomic neuropathy in the subject.
A method of inhibiting expression of a TTR gene in a cell comprising treating the cell with the above UNA oligomer.
A method of inhibiting expression of a TTR gene in a mammal comprising administering the above UNA oligomer to the mammal.
A method of inhibiting expression of a gene in a plant comprising applying to the plant a UNA oligomer of 10 to 1000 base pairs in length.
Drawings
FIG. 1: FIG. 1 shows that UNA oligomers demonstrated unexpectedly reduced off-target activity on ApoCIII mRNA expression in a dual-luciferase reporter assay using the PSICHECK-2 vector (Promega). In particular, and at the 5' end site in the passenger chainComparative UNA oligomer ATS98 without UNA monomerSite at the 5' end of passenger chain
FIG. 2: FIG. 2 shows that UNA oligomers demonstrated unexpectedly reduced off-target activity on ApoCIII mRNA expression in a dual luciferase reporter assay using the PSICHECK-2 vector. In particular, and at the 5' end site in the passenger chain
FIG. 3: figure 3 shows that, for TTR mRNA expression, certain UNA oligomers have at least comparable levels of knockdown activity as conventional siRNA. Specifically, UNA oligomer ATX13 containing a UNA monomer at the 5 'end of the first strand and UNA oligomer ATX15 containing a UNA monomer at the 5' end of the first strand and two UNA monomers at the 20 th and 21 st positions from the 5 'end at the 3' end of the second strand had at least comparable levels of knockdown activity compared to conventional siRNA ATS-91. Furthermore, UNA oligomer ATX21 containing a UNA monomer at the 5 ' end of the first strand, one at the 20 th position from the 5 ' end at the 3' end of the first strand, and one at the 20 th position from the 5 ' end at the 3' end of the second strand, had at least comparable levels of knockdown activity compared to conventional siRNA ATS-91. Furthermore, ATX25 containing a UNA monomer at the 5 ' end of the first strand, one UNA monomer at the 20 th position from the 5 ' end at the 3' end of the first strand, and one UNA monomer at the 20 th position from the 5 ' end at the 3' end of the second strand, had at least comparable levels of knockdown activity in a head-to-head comparison as compared to conventional siRNA ATS-92.
FIG. 4: FIG. 4 shows the structures of UNA oligomers ATX13, ATX15 and
FIG. 5: figure 5 shows a scheme for measuring off-target (OT) effects. A dual luciferase reporter assay using the PSICHECK-2 vector (Promega) was established to quantify off-target effects. For each measurement, 4 plasmids were constructed: (ii) guide strand GSCM and guide strand GSSM knocked down for the second strand or antisense strand; and passenger strand PSCM and passenger strand PSSM knocked down for the first strand or sense strand. The reporter plasmid was co-transfected with UNA oligomer into HeLa cells. In this system, if a UNA oligomer binds to a target sequence inserted into the luciferase 3-UTR, the chemiluminescent signal is reduced or eliminated.
FIG. 6: figure 6 shows the structure of UNA oligomers for head-to-head comparison of knockdown levels with conventional siRNA. UNA oligos were plated around 284 of the 625 to 651 positions of the TTR mRNA region. 5 UNA oligomers were prepared, namely ATX25, ATX37, ATX21, ATX38 and ATX 39. These UNA oligomers were tested for off-target effects compared to conventional siRNA targeting the same site.
FIG. 7: figure 7 shows the structure of an embodiment of UNA oligomers with reduced off-target effects.
FIG. 8: figure 8 shows the results of a head-to-head comparison of UNA oligomer ATX25 with conventional siRNA ATS92 for off-target effects in knockdown of TTR expression. UNA oligomer ATX25 had increased knockdown compared to conventional sirna (gscm). Surprisingly, UNA oligomer ATX25 had reduced off-target knockdown compared to conventional sirna (pscm).
FIG. 9: figure 9 shows the results of a head-to-head comparison of UNA oligomer ATX37 with conventional siRNAATS104 for off-target effects in knockdown of TTR expression. UNA oligomer ATX37 had increased knockdown compared to conventional sirna (gscm). Surprisingly, UNA oligomer ATX37 had a greatly reduced off-target knockdown compared to conventional sirna (pscm).
FIG. 10: figure 10 shows the results of a head-to-head comparison of UNA oligomer ATX21 with conventional siRNA ATS91 for off-target effects in knockdown of TTR expression. UNA oligomer ATX21 has a knockdown comparable to conventional sirna (gscm). Surprisingly, UNA oligomer ATX21 had a greatly reduced off-target knockdown compared to conventional sirna (pscm).
FIG. 11: figure 11 shows the results of a head-to-head comparison of UNA oligomer ATX38 with conventional siRNA ATS105 for off-target effects in knockdown of TTR expression. UNA oligomer ATX38 had increased knockdown compared to conventional sirna (gscm). Surprisingly, UNA oligomer ATX38 had a greatly reduced off-target knockdown compared to conventional sirna (pscm).
FIG. 12: figure 12 shows the results of a head-to-head comparison of UNA oligomer ATX39 with conventional siRNA ATS106 for off-target effects in knockdown of TTR expression. UNA oligomer ATX39 had comparable knockdown compared to conventional sirna (gscm). Surprisingly, UNA oligomer ATX39 had a greatly reduced off-target knockdown compared to conventional sirna (pscm).
FIG. 13: figure 13 shows that certain UNA oligomers demonstrate unexpectedly reduced off-target effects. In particular, the presence of a combination of UNA monomers in three positions of the UNA oligomer, more specifically, at the 5 ' and 3' ends of the passenger strand and at the 3' end of the guide strand, was shown to provide unexpectedly reduced off-target knockdown activity of the passenger strand.
Detailed Description
The present invention provides UNA oligomers as agents for gene silencing and methods of using the UNA oligomers for treating or preventing diseases. UNA oligomers of the invention can have reduced off-target effects in gene silencing.
The UNA oligomers of the invention are Unlocked Nucleomonomer Activators (UNA) described in detail below. UNA oligomers are chain molecules comprising one or more UNA monomers. UNA monomers are small organic molecules based on propane-1, 2, 3-tri-yl-trioxy structures. UNA oligomers can be chains consisting of UNA monomers as well as different or modified nucleotides that can be based on naturally occurring nucleosides.
In some aspects, the invention provides for the treatment of amyloidosis. More specifically, the invention relates to methods of treating transthyretin-associated amyloidosis with UNA oligomers that have reduced off-target effects in the knockdown of transthyretin.
In certain aspects, UNA oligomers of the invention can be used for gene silencing in plants. UNA oligomers used in plants can have a length of 10 to 1000 base pairs. UNA oligomers of the invention can be used in functional genomics in plants, for controlling plant traits, for providing resistance to viruses and pathogens, or for providing protection against insects, etc., while providing reduced off-target effects.
UNA oligomers of the invention can be active for specific gene knockdown with reduced off-target effects.
In some embodiments, the UNA oligomer targets a gene target identified as a disease target.
In certain embodiments, UNA oligomers of the present disclosure can target The Transthyretin (TTR) gene.
In other embodiments, UNA oligomers of the present disclosure can target apolipoprotein genes, such as ApoCIII.
Transthyretin-associated Amyloidosis (ATTR) involves the deposition of amyloid fibrin in various organs and tissues, including the peripheral nervous system, the autonomic nervous system, and the central nervous system. Transthyretin (TTR) is a secreted thyroid hormone binding protein that binds to and transports retinol binding protein and serum thyroxine in plasma and cerebrospinal fluid.
Symptoms of ATTR typically include neuropathy and/or cardiomyopathy. Peripheral neuropathy may begin in the lower extremities, which have sensory neuropathy and motor neuropathy, and can progress to the upper extremities. Autonomic neuropathy may manifest as gastrointestinal symptoms and orthostatic hypotension.
The most common mutation of the TTR gene is Val-30-Met in patients with ATTR. The primary therapy for ATTR amyloidosis is liver transplantation, which removes the primary source of variant TTR production and replaces it with normal TTR. No pharmacotherapy exists that is capable of resolving TTR amyloid formation.
In some embodiments, the invention provides agents for effectively silencing genes and knocking down TTRs with reduced off-target effects.
In some embodiments, UNA oligomers are provided for use in treating transthyretin-associated Amyloidosis (ATTR). UNA oligomers of the invention can reduce amyloid fibrin deposition in various organs and tissues, including the peripheral nervous system, autonomic nervous system, and central nervous system.
In certain aspects, the invention provides for the treatment of ATTR and related amyloid associated diseases.
Aspects of the invention include UNA oligomers that can be used to treat clinical features of ATTR amyloidosis, including neuropathy and/or cardiomyopathy.
In some embodiments, a UNA oligomer of the invention targets a mutant Val-30-Met TTR.
The present invention may provide pharmacological therapies capable of abrogating TTR amyloid formation.
UNA monomer
UNA monomers are small organic molecules based on propane-1, 2, 3-tri-yl-trioxane structures shown below:
wherein R is1And R2Is HAnd R is1And R2May be a phosphodiester bond, the base may be a nucleobase, and R3 is a functional group described below.
In another perspective, the main atoms of UNA monomers can be drawn in the IUPAC notation as follows:
wherein the oligomer chain advances from 1 to 3 ends of the propane residue.
Examples of nucleobases include uracil, thymine, cytosine, 5-methylcytosine, adenine, guanine, inosine, and natural and non-natural nucleobase analogs.
In general, since UNA monomers are not nucleotides, they can exhibit at least four forms in oligomers. First, the UNA monomer can be an internal monomer in an oligomer, wherein the UNA monomer is flanked by additional monomers. In this form, UNA monomers can participate in base pairing when the oligomer is, for example, a duplex in which other monomers having nucleobases are present.
Examples of UNA monomers that are pendant to the propane-1-yl site and the propane-3-yl site as internal monomers are shown below, where R3 is-OH.
Second, the UNA monomer can be a monomer in the overhang of the oligomeric duplex, wherein the UNA monomer is flanked by additional monomers. In this form, UNA monomers do not participate in base pairing. Since UNA monomers are flexible organic structures, unlike nucleotides, overhangs comprising UNA monomers will be flexible terminators for oligomers.
The UNA monomer can be a terminal monomer in an overhang of the oligomer, wherein the UNA monomer is attached to only one monomer at the propane-1-yl site or the propane-3-yl site. In this form, UNA monomers do not participate in base pairing. Since UNA monomers are flexible organic structures, unlike nucleotides, overhangs comprising UNA monomers can be flexible terminators of oligomers.
Examples of UNA monomers attached as terminal monomers at the propane-3-yl site are shown below.
As UNA monomers can be flexible molecules, UNA monomers as terminal monomers can assume a wide variety of conformations. Examples of UNA monomer configurations that minimize energy attachment as a terminal monomer at the propane-3-yl site are shown below.
Thus, UNA oligomers with terminal UNA monomers are structurally significantly different from conventional nucleic acid agents, such as sirnas. For example, siRNA may require that the terminal monomer or overhang in the duplex be stable. Conversely, compliance of terminal UNA monomers can provide UNA oligomers with different properties.
The structure of the UNA monomer allows, among other things, its linkage to naturally occurring nucleotides. UNA oligomers can be chains composed of UNA monomers as well as different nucleotides that can be based on naturally occurring nucleosides.
In some embodiments, functional group R of UNA monomer3May be-OR4、-SR4、-NR4 2、-NH(C＝O)R4Morpholino, morpholin-l-yl, piperazin-l-yl or 4-alkanoyl-piperazin-l-yl, wherein for each occurrence R4The same or different and may be H, a hydrocarbon group, cholesterol, a lipid molecule, a polyamine, an amino acid, or a polypeptide.
UNA monomers are organic molecules. UNA monomers are not nucleic acid monomers or nucleotides, nor are naturally occurring nucleosides or modified naturally occurring nucleosides.
The UNA oligomers of the invention are synthetic chain molecules. UNA oligomers of the invention are neither nucleic acids nor oligonucleotides.
In some embodiments, as shown above, the UNA monomer can be UNA-a (designated)
Designations useful herein include mA, mG, mC, and mU, which refer to 2' -O-methyl modified ribonucleotides.
Designations useful herein include the lower case c and u, which refer to 2' -O-methyl modified ribonucleotides.
Designations useful herein include dT, which refers to 2' -deoxyt nucleotides.
Monomers of UNA oligomers
As used herein, in the context of oligomer sequences, the symbol X represents a UNA monomer.
As used herein, in the context of oligomer sequences, the symbol N represents any natural or modified nucleotide monomer.
As used herein, in the context of oligomer sequences, the symbol Q represents a non-naturally occurring nucleotide monomer, a modified nucleotide monomer, or a chemically modified nucleotide monomer.
Examples of non-natural, modified, and chemically modified nucleotide monomers include: 2 '-O-methyl ribonucleotides, 2' -O-methyl purine nucleotides, 2 '-deoxy-2' -fluoro ribonucleotides, 2 '-deoxy-2' -fluoro pyrimidine nucleotides, 2 '-deoxy ribonucleotides, 2' -deoxy purine nucleotides, universal base nucleotides, 5-C-methyl-nucleotides, and inverted deoxy base monomer residues.
Examples of non-natural, modified, and chemically modified nucleotide monomers include 3 '-end-stable nucleotides, 3' -glyceryl nucleotides, 3 '-inverted abasic nucleotides, and 3' -inverted thymidine.
Examples of non-natural, modified, and chemically modified nucleotide monomers include locked nucleic acid nucleotides, 2 ' -O,4 ' -C-methylene- (D-furonitrosourea) nucleotides, 2 ' -Methoxyethoxy (MOE) nucleotides, 2 ' -methyl-thio-ethyl, 2 ' -deoxy-2 ' -fluoro nucleotides, and 2 ' -O-methyl nucleotides.
Examples of non-natural, modified, and chemically modified nucleotide monomers include 2 '-amino nucleotides, 2' -O-amino nucleotides, 2 '-C-allyl nucleotides, and 2' -O-allyl nucleotides.
Examples of non-natural, modified and chemically modified nucleotide monomers include N6-methyladenosine nucleotides.
Examples of non-natural, modified, and chemically modified nucleotide monomers include nucleotide monomers that contain modified bases as follows: 5- (3-amino) propyluridine, 5- (2-mercapto) ethyluridine, 5-bromouridine; 8-bromoguanosine or 7-deazaadenosine.
Examples of non-natural, modified, and chemically modified nucleotide monomers include 2' -O-aminopropyl substituted nucleotides.
Examples of non-natural, modified, and chemically modified nucleotide monomers include replacing the 2' -OH group of a nucleotide with: 2 ' -R, 2 ' -OR, 2 ' -halo, 2 ' -SR, OR 2 ' -amino, wherein R can be H, alkyl, alkenyl, OR alkynyl.
Some examples of modified nucleotides are given in Saenger, Principles of Nucleic Acid Structure, Springer-Verlag, 1984.
UNA oligomers
UNA oligomers of the invention are chain molecules. UNA oligomers can be duplex pairs. Thus, a UNA oligomer may contain a first strand of the duplex and a second strand of the duplex that is complementary to the first strand, although up to 3 mismatches may be present. UNA oligo duplexes may contain overhangs.
Some UNA oligomers are discussed in U.S. patent No. 8,314,227, and U.S. patent application No. 20110313020 Al.
The target of the UNA oligomer can be a target nucleic acid. In some embodiments, the target may be any mRNA of the subject. UNA oligomers can be active for gene silencing in RNA interference.
UNA oligomers may comprise two strands that together provide a duplex. A duplex may be composed of a first strand, which may also be referred to as a passenger strand or sense strand, and a second strand, which may also be referred to as a guide strand or antisense strand.
In some aspects, UNA oligomers of the invention can contain any number of phosphorothioate inter-monomer linkages at any position on any or both strands of the duplex structure.
Examples of UNA oligomers of the invention include pairs of duplexes, which are generally complementary. Thus, for example, SEQ ID NO:1 may represent a first strand of a duplex and SEQ ID NO:2 may represent a second strand of a duplex, said second strand being complementary to said first strand.
For example, the symbol "N" in the first strand may represent any nucleotide that is complementary to the monomer at the corresponding site in the second strand. Exemplary UNA oligomers of the present disclosure are shown having overhangs of 2 monomers in length, although overhangs of up to 8 monomers or longer may be used.
"X" in a chain or oligomer represents a UNA monomer.
Furthermore, when the oligomer terminates in the UNA monomer, the terminal site has a 1-terminus instead of a 5 '-terminus according to the position numbering shown above for nucleotides, or a 3-terminus instead of a 3' -terminus according to the position numbering shown above for nucleotides. For example, a UNA oligomer has a UNA monomer at the 1 end of the first strand, a UNA monomer at the 3 end of the second strand, and a nucleotide at the 5' end of the second strand.
SEQ ID NO：1
1-X·N·N·N·N·N·N·N·N·N·N·N·N·N·N·N·N·N·N·N·X·X-3
3-X·X·N·N·N·N·N·N·N·N·N·N·N·X·X·X·X·X·X·X·N-5′
SEQ ID NO：2
In some embodiments, a UNA oligomer of the invention can contain one or more UNA monomers at the 1-terminus of the first strand, and one or more UNA monomers at the 3-terminus of the first strand.
In other embodiments, a UNA oligomer of the invention can contain one or more UNA monomers at the 3-terminus of the second strand.
In certain embodiments, a duplex UNA oligomer of the invention can contain one or more UNA monomers at the 1-terminus of the first strand, at the 3-terminus of the first strand, and at the 3-terminus of the second strand.
UNA oligomers of the invention can comprise a first strand and a second strand, each strand independently being 19-23 monomers in length.
In certain embodiments, UNA oligomers of the invention can comprise a first strand that is 19-23 monomers in length.
In certain embodiments, UNA oligomers of the invention can contain duplex regions that are 19-21 monomers in length.
In other embodiments, UNA oligomers of the invention can contain a second strand that is 19-23 monomers in length.
In certain embodiments, UNA oligomers of the invention can contain a first strand that is 19 monomers in length, and a second strand that is 21 monomers in length.
In certain embodiments, UNA oligomers of the invention can contain a first strand that is 20 monomers in length, and a second strand that is 21 monomers in length.
In certain embodiments, UNA oligomers of the invention can contain a first strand that is 21 monomers in length, and a second strand that is 21 monomers in length.
In certain embodiments, UNA oligomers of the invention can contain a first strand that is 22 monomers in length, and a second strand that is 21 monomers in length.
The UNA oligomers of the invention for inhibiting gene expression may comprise a first strand and a second strand, each of 19-29 monomers in length. The monomers can be UNA monomers and nucleic acid monomers. The oligomer may have a double helix structure of 14 to 29 monomers in length. UNA oligomers can target genes and can exhibit reduced off-target effects compared to conventional siRNA. In some embodiments, UNA oligomers of the invention can comprise a first strand and a second strand, each of which is 19-23 monomers in length.
In another aspect, the UNA oligomer can have blunt ends, or can contain one or more overhangs. In some embodiments, the first strand and the second strand may be joined to a linker oligomer between the two strands and form a duplex region with a connecting loop at one end.
In certain embodiments, the length of the overhang may be one or two monomers.
UNA oligomers can mediate cleavage of target nucleic acids in cells. In some processes, a second strand of the UNA oligomer (at least a portion of which can be complementary to the target nucleic acid) can function as a guide strand capable of hybridizing to the target nucleic acid.
The second strand may be incorporated into the RNA-induced silencing complex (RISC).
UNA oligomers of the present disclosure can comprise naturally occurring nucleic acid nucleotides, as well as modifications thereof compatible with gene silencing activity.
In some aspects, the UNA oligomer is a double-stranded construct molecule capable of inhibiting gene expression.
The term chain as used herein refers to a single continuous chain of monomers, said chain containing any number of internal monomers and two terminal monomers, wherein each terminal monomer is attached to an internal monomer on one side and not to a monomer on the other side, whereby said terminal monomer terminates the chain.
The monomers of the UNA oligomer can be linked by phosphodiester linkages, phosphorothioate linkages, gapped linkages, and other variations.
In some embodiments, the UNA oligomer can comprise a mismatch in the complementarity between the first strand and the second strand. In other embodiments, UNA oligomers may contain 1, or 2, or 3 mismatches. Mismatches may occur at any site in the duplex region.
The target of the UNA oligomer can be a target nucleic acid of a target gene.
UNA oligomers may contain one or two overhangs outside the duplex region. The overhang may be a non-pairing moiety located at the end of the first strand or the second strand. The length of the overhang portions of the first and second strands may be the same or different.
UNA oligomers may have at least one blunt end. The blunt end has no overhang portion, and the regions of the double helix located at the blunt end terminate at the same site on the first strand and the second strand.
UNA oligomers can be RISC long, meaning they have a duplex less than 25 base pairs in length.
In certain embodiments, the UNA oligomer can be single stranded, which folds upon itself and hybridizes to itself to form a double stranded region with a connecting loop.
Examples of UNA oligomer structures with reduced off-target effects are shown in table 1.
Table 1: UNA oligomers with reduced off-target effects
In some embodiments, a UNA oligomer with reduced off-target effects can contain UNA monomers at the first position at the 1-terminus of the first strand (also referred to as the passenger strand), and at one or both of the last two positions at the 3-terminus of the first strand, and at one or both of the last two positions at the 3-terminus of the second strand (also referred to as the guide strand). For example, SEQ ID NO: 3 and 4, wherein the UNA monomers are present at both the last two positions at the 3-terminus of the first strand and at the last two positions at the 3-terminus of the second strand.
In some embodiments, UNA oligomers with reduced off-target effects can contain UNA monomers at the first position at the 1-terminus of the first strand and at one or both of the last two positions at the 3-terminus of the first strand. For example, SEQ ID NO: 5 and 6, wherein the last two sites at the 3-terminus of the first strand are both UNA monomers.
In some embodiments, UNA oligomers with reduced off-target effects can contain UNA monomers at the first position at the 1 end of the first strand (also referred to as the passenger strand) and at one or both of the last two positions at the 3 end of the second strand. For example, SEQ ID NO: 7 and 8, wherein the last two sites at the 3-terminus of the second strand are both UNA monomers.
In some embodiments, UNA oligomers with reduced off-target effects can contain an UNA monomer at the first position at the 1-terminus of the first strand. For example, SEQ ID NO: 9 and 10.
In some embodiments, UNA oligomers with reduced off-target effects can contain UNA monomers at one or both of the last two positions at the 3-terminus of the first strand and one or both of the last two positions at the 3-terminus of the second strand. For example, SEQ ID NO: 11 and 12, wherein the last two sites at the 3-terminus of the first strand and the last two sites at the 3-terminus of the second strand are UNA monomers.
In some embodiments, a UNA oligomer with reduced off-target effects can contain UNA monomers in the seed region at any one or more of positions 2-8 of the 5' end of the second strand, in addition to containing one or more UNA monomers at any of the positions described above.
Examples of UNA oligomer structures with reduced off-target effects are shown in table 2.
Table 2: UNA oligomers with reduced off-target effects
Methods of treating amyloidosis
The methods of the invention comprise treating and preventing TTR-associated amyloidosis in a mammalian subject with reduced off-target effects.
In the methods of the invention, an effective amount of a UNA oligomer can be administered to a subject in need of treatment or prevention. The subject may be a human or a mammal.
The subject may have TTR-associated amyloidosis, also known as ATTR.
In particular, the subject may contain the V30M gene. The methods of the invention can reduce V30M TTR in a subject with reduced off-target effects.
In some embodiments, the methods of the invention can reduce TTR or V30M TTR in a subject by at least 10% with reduced off-target effects compared to a control. In certain embodiments, TTR or V30M TTR may be reduced in a subject by at least 20%, or 30%, or 50% with reduced off-target effects as compared to a control.
An effective amount of a UNA oligomer of the invention can be in a dosage range of 0.001mg/kg to 50.0 mg/kg.
In the methods of the invention, expression of TTR mRNA in the subject may be decreased for at least 5 days. In certain embodiments, TTR mRNA expression in a subject may be decreased for at least 10 days or 15 days.
In the methods of the invention, peripheral neuropathy or autonomic neuropathy in a subject can be reduced.
In the methods of the invention, peripheral neuropathy or autonomic neuropathy in a subject can be reduced. In some embodiments, the subject may experience reduced lower limb weakness, reduced pain, or improved sensation. The method of the present invention can reduce the occurrence of vitreous opacity in a subject.
In the methods of the present disclosure, administration of UNA oligomers may not result in an inflammatory response.
In other embodiments, the invention includes methods of inhibiting TTR gene expression in a cell by treating the cell with a UNA oligomer.
In other embodiments, the invention includes methods of inhibiting TTR gene expression in a mammal by administering to the mammal a composition comprising a UNA oligomer.
Pharmaceutical composition
In some aspects, the invention provides a pharmaceutical composition comprising a UNA oligomer and a pharmaceutically acceptable carrier.
The pharmaceutical composition may be capable of local administration or systemic administration. In some aspects, the pharmaceutical composition may be capable of being administered in any form. In certain aspects, administration can be intravenous, subcutaneous, pulmonary, intramuscular, intraperitoneal, dermal, oral, or nasal.
Embodiments of the invention include pharmaceutical compositions comprising UNA oligomers in the form of lipid formulations.
In some embodiments, the pharmaceutical composition may comprise one or more lipids selected from the group consisting of: cationic lipids, anionic lipids, sterols, pegylated lipids, and any combination of the foregoing.
In certain embodiments, the pharmaceutical composition may be substantially free of liposomes.
In other embodiments, the pharmaceutical composition may comprise liposomes.
In other embodiments, the pharmaceutical composition can comprise UNA oligomers within a viral or bacterial vector.
The pharmaceutical compositions of the present disclosure may comprise carriers, diluents or excipients known in the art. Examples of Pharmaceutical compositions are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing co. (a.r. gennaro ed.1985).
Examples of excipients for pharmaceutical compositions include antioxidants, suspending agents, dispersing agents, preservatives, buffers, tonicity agents and surfactants.
Examples